Home/Pipeline/HBI-002

HBI-002

Parkinson's Disease

Phase 2aActive

Key Facts

Indication

Parkinson's Disease

Phase

Phase 2a

Status

Active

Company

Hillhurst Biopharmaceuticals

About Hillhurst Biopharmaceuticals

Hillhurst Biopharmaceuticals is pioneering the oral delivery of therapeutic gases through its GLASS technology platform, moving beyond traditional inhalation methods. Founded in 2018, the company has advanced into clinical stages, with a Phase 2a trial cleared for its Parkinson's disease candidate and a pipeline targeting sickle cell disease and acute pain. It is a privately held, pre-revenue company backed by non-dilutive grant funding from foundations and government sources, led by a team with deep experience in hematology, commercialization, and drug development.

View full company profile

Therapeutic Areas

Sickle Cell Disease Parkinson's Disease Acute Pain Diabetic Retinopathy

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active